Metraipolis › archive › dc_1322fdf44d44
Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study — Europe PMC PMID:34673776
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/34673776
- DOI
- 10.1371/journal.pone.0250681
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-02T06:51:19.112Z
- SHA-256 of the archived text
db8383ffc490ca48c92ce01c5c30ca74946a6bcb0d1ba15b710f3529111b60f2- Stable URL of this page
https://metraipolis.com/documento/dc_1322fdf44d44
How to cite
Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study — Europe PMC PMID:34673776 — Europe PMC (en), https://europepmc.org/article/MED/34673776 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_1322fdf44d44 (Metraipolis archive dc_1322fdf44d44, sha256 db8383ffc490ca48c92ce01c5c30ca74946a6bcb0d1ba15b710f3529111b60f2)
BibTeX
@misc{dc1322fdf44d44,
title = {Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study — Europe PMC PMID:34673776},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/34673776},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_1322fdf44d44; sha256 db8383ffc490ca48c92ce01c5c30ca74946a6bcb0d1ba15b710f3529111b60f2},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34673776. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Induction of remission is easily achieved with dietary treatment in dogs diagnosed with Food Responsive Chronic Diarrhea (FRD). Administration of prebiotics and glycosaminoglycans (GAGs) may improve epithelial cell integrity and therefore be useful as adjunct treatment. This study evaluated whether the relapse rate of FRD dogs that are switched back to a normal diet can be influenced using supplemental treatment with prebiotics and GAGs. A randomized, controlled clinical trial (RCCT) was performed in dogs diagnosed with FRD. Dogs were diagnosed based on clinical exclusion diagnosis, endoscopic biopsies showing predominantly lymphoplasmacytic infiltration, and response to dietary treatment. Dogs were randomized to be fed a combination of prebiotics and GAGs (group 1) or placebo (group 2) in addition to a hydrolyzed diet. At week 10, a second endoscopy was performed and dogs were switched back to normal diet. Relapse rate was monitored every 2 weeks after that until week 18. Statistical analysis was performed for each outcome (Canine Chronic Enteropathy Clinical Activity Index (CCECAI), clinicopathological data, endoscopic scoring, mWSAVA histological scoring index (mWSAVA), and number of relapses following switch to normal diet) using a linear mixed effects model for group comparison. Time, group, and their interactions were included as a fixed effect, whereas each dog was treated as a random effect. Of the 35 dogs enrolled into the clinical trial, 10 in each group reached the point of second endoscopy. A total of 13 dogs (n = 8 in group 1 and n = 5 in group 2) reached the trial endpoint of 18 weeks. After switching back to normal diet, none of the dogs in either group relapsed. No significant differences were found over time or between groups for CCECAI, endoscopy scoring and histological scoring. Although there was a clinical worsening in the placebo group after switching back to the original diet, this was not statistically significant (CCECAI p = 0.58). Post-hoc power calculation revealed that 63 dogs per group would have been needed to detect statistically significant differences in CIBDAI between treatment groups. Standard dietary treatment induced rapid clinical response in all cases, however, additional supplementation with prebiotics and GAGs did not significantly improve clinical outcome within 4 months after switching back to normal diet. Since there are very few RCCT published in CE in dogs, this pilot study provides important power analyses for planning of further studies. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-10-21). Identificativi: PMID 34673776 · PMCID PMC8530283 · DOI 10.1371/journal.pone.0250681. Descrittori MeSH principali: Dog Diseases; Glycosaminoglycans; Prebiotics. Pagina: https://europepmc.org/article/MED/34673776 — https://doi.org/10.1371/journal.pone.0250681. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-02T06:42:43.091Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.